Current Edition

Bavencio

ESMO: Bristol Myers’ Opdivo-Yervoy, Pfizer-Merck KGaA’s Bavencio hit walls in head and neck cancer

Suffering two separate clinical trial blows, Bristol Myers Squibb and a collaboration between Merck KGaA and Pfizer learned the hard way that head and neck …

Continue Reading →
Bristol Myers

Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028

As a top-selling drug worldwide, Pfizer and Bristol Myers Squibb’s Eliquis is a major target for generic players looking to steal branded sales. But with …

Continue Reading →
Bristol Myers

Novartis’ Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeeded

Novartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb …

Continue Reading →